NEUROSEARCH A/S 
By
At the company's Extraordinary General Meeting today, attorney-at-law Christian Lundgren was elected to the Board of Directors of NeuroSearch.
On the same occasion, the shareholder-elected members Thomas Hofman-Bang, Anders Ullman and Ian Talmage and the employee-elected member Morten Nielsen resigned from the Board of Directors.
Subsequently, the Board of Directors now consists of the shareholder-elected Board members Allan Andersen, Torbjørn Bjerke and Christian Lundgren and the employee-elected Board members Lars S. Madsen and Mads G. Korsgaard.
Immediately after the general meeting, the Board convened and elected Allan Andersen as new Chairman of the Board.
René Schneider
CEO
Contact person:
René Schneider, CEO, telephone: +45 4460 8700 or +45 2911 2097
About NeuroSearch
NeuroSearch A/S (NEUR) is listed on NASDAQ OMX Copenhagen A/S. The company's product pipeline comprises ordopidine and seridopidine, which have both completed phase I studies, as well as tesofensine, which has completed phase II, and NS2359 which has completed phase I. All drug candidates exert their effect in the central nervous system.
On the same occasion, the shareholder-elected members Thomas Hofman-Bang, Anders Ullman and Ian Talmage and the employee-elected member Morten Nielsen resigned from the Board of Directors.
Subsequently, the Board of Directors now consists of the shareholder-elected Board members Allan Andersen, Torbjørn Bjerke and Christian Lundgren and the employee-elected Board members Lars S. Madsen and Mads G. Korsgaard.
Immediately after the general meeting, the Board convened and elected Allan Andersen as new Chairman of the Board.
René Schneider
CEO
Contact person:
René Schneider, CEO, telephone: +45 4460 8700 or +45 2911 2097
About NeuroSearch
NeuroSearch A/S (NEUR) is listed on NASDAQ OMX Copenhagen A/S. The company's product pipeline comprises ordopidine and seridopidine, which have both completed phase I studies, as well as tesofensine, which has completed phase II, and NS2359 which has completed phase I. All drug candidates exert their effect in the central nervous system.
|
distributed by
|
